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Ivermectin is being considered for mass-drug-administration for malaria due to its ability to kill 
mosquitoes feeding on recently treated individuals. However, standard, single-doses of 150-200 
mcg/kg used for onchocerciasis and lymphatic filariasis have a short-lived mosquitocidal-effect (<7 
days). Ivermectin is well-tolerated up to 2,000 mcg/kg. Multi-day regimens of high-doses of 
ivermectin could generate longer mosquitocidal-effects required for malaria elimination.  
Methods 
Randomized, double-blind, placebo-controlled trial comparing the safety, tolerability, and efficacy of 
3-day ivermectin 0, 300, or 600 mcg/kg/day, co-administered with dihydroartemisinin-piperaquine, 
in randomly assigned (1:1:1) adults with uncomplicated malaria in Kenya. Randomisation lists were 
computer-generated. Sequentially numbered, opaque envelopes concealed allocation. Patients’ 
blood taken on post-treatment days 0, 2+4h (Cmax), 7, 10, 14, 21, and 28, was fed to laboratory-
reared Anopheles gambiae s.s.; mosquito survival was assessed daily for 28-days post-feeding. The 
primary outcome was 14-day-cumulative-mortality of mosquitoes fed 7-days post-treatment; 
secondary outcomes included 14-day-survival-time of mosquitoes fed at each post-treatment visit. 
Safety outcomes included pupil-diameter, QT-interval, and adverse events. Analyses were by 
intention-to-treat. Ivermectin’s effect on malaria transmission was modelled. Trial 
registration:ClinicalTrials.gov-NCT02511353. 
Findings 
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Between 20-Jul-2015 and 07-May-2016, 141 patients were randomized to ivermectin 600 
mcg/kg/day (n=47), 300 mcg/kg/day (n=48), or placebo (n=46). 128 patients (90.8%) attended the 
primary outcome visit 7-days post-treatment. Compared to placebo, ivermectin was associated with 
higher 14-day-post-feeding mosquito mortality when fed on blood taken 7-days-post-treatment (600 
mcg/kg/day: risk ratio [RR] 2.26, 95% confidence interval [1.93-2.65], p<0.0001; hazard ratio [HR] 
6.32 [4.61-8.67], p<0.0001; 300 mcg/kg/day: RR=2.18 [1.86-2.57], p<0.0001; HR=4.21 [3.06-5.79], 
p<0.0001). Mosquito mortality remained significantly increased 28-days-post-treatment. The 
incidence of related adverse events were: 5/45 (11%), 2/48 (4%), and 0/46 (0%) with 600, 300, and 0 
mcg/kg/day. Ivermectin didn’t modify piperaquine’s QT-prolonging-effect. Modelling predicted that 
adding 3-day ivermectin 600 or 300 mcg/kg/day to mass drug administration with 
dihydroartemisinin-piperaquine enhances malaria prevalence reduction by an additional 56% (600 
mcg) and 44% (300 mcg) in low prevalence areas (10%), and 61% (600 mcg) and 54% (300 mcg) in 
high prevalence areas (30%). 
Interpretation 
3-day ivermectin at both 600 and 300 mcg/kg/day is well tolerated and reduces mosquito survival 
for at least 28-days-post-treatment. The latter regimen would provide a good balance between 
efficacy and tolerability. Ivermectin shows promise as a potential new tool for malaria elimination. 
Funding 
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Background 
Ivermectin, a broad spectrum antiparasitic endectocide used for onchocerciasis and lymphatic 
filariasis control,1 also kills malaria mosquitoes (Anopheles spp.) feeding on recently treated 
individuals and has been proposed as a potential novel tool to reduce malaria transmission.2 It has a 
different mode of action than other insecticides, and may be effective against mosquito populations 
that rest and feed outdoors which escape the killing effects of contact insecticides deployed on long-
lasting insecticidal nets (LLINs) and through indoor residual spraying (IRS), as well as against 
mosquitoes that are resistant to insecticides used for LLINs and IRS.3  
However, several entomological studies have shown that the mosquitocidal effects of 
standard 150-200 mcg/kg doses of ivermectin are short-lived (<7 days).4-9 Population-level modelling 
suggests higher doses of ivermectin, resulting in longer lasting mosquitocidal activity, could provide 
a significant boost to the impact of Mass Drug Administration (MDA) with the antimalarial 
dihydroartemisinin-piperaquine (DP), a strategy that is currently being deployed for malaria 
transmission reduction and elimination.10, 11  
Ivermectin has an excellent safety profile.2 To date more than 2.5 billion treatments have 
been distributed as part of MDA for onchocerciasis and lymphatic filariasis control.12 A single-dose of 
300-400 mcg/kg is recommended for these MDA’s when conducted yearly,13 a dose of 400 mcg/kg 
repeated after 1 week has been shown safe and effective in children with head lice,14 and doses of 
800 mcg/kg repeated yearly or 3-monthly were safely tested in hundreds of adults with 
onchocerciasis.15-19 Experience with higher doses shows that it is remarkably well tolerated in 
humans,15-20 up to 2,000 mcg/kg,20 i.e. ten times the dose currently approved by the US Food and 
Drug Administration.  
We conducted a trial to determine the safety, tolerability and mosquitocidal efficacy of 3-
day courses of ivermectin 600 or 300 mcg/kg/day, co-administered with a standard 3-day course of 
DP to identify safe and practical regimens for malaria elimination.  
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Research in context 
Evidence before this study 
We searched PubMed on Nov 15, 2017 for studies assessing Anopheles mortality following 
feeding on blood of humans treated with ivermectin. We used the search terms: ivermectin AND 
(anopheles OR malaria) AND “clinical trial”[publication type]. The search 
was unrestricted by language or publication date. Through this search, and by scanning reference 
lists of articles and trial registers, we identified a total of three publications in peer reviewed 
journals. An early study found that a single-dose of 250 mcg/kg in a human volunteer (N=1) had 
an effect for 2 weeks post-treatment, but subsequent trials with a single-dose 200 mcg/kg showed 
no effect on mosquito survival at 14 days post-treatment and a repeated dose of 200 mcg/kg 
given on days 0 and 2 showed only a modest effect on survival 7 days post-treatment. Population 
modelling predicted that the mosquitocidal effects found in these trials would only have a limited 
effect on reducing malaria prevalence if distributed in mass drug administration with 
dihydroartemisinin-piperaquine, while higher doses of ivermectin were predicted to have a 
greater and longer-lasting effect. 
Added value of this study 
We present the first trial assessing the safety, tolerability, and mosquitocidal efficacy of repeated, 
high-doses of ivermectin on mosquito mortality. 
Implications of all the available evidence 
Our findings show that ivermectin at both 600 and 300 mcg/kg/day for 3 days is well tolerated 
and increases mosquito mortality for at least 28 days post-treatment, making ivermectin a 
promising new tool for malaria elimination. Using population-level modelling, we also show that 
adding ivermectin 600 or 300 mcg/kg/day for 3 days to mass drug administration with 
dihydroartemisinin-piperaquine reduces malaria prevalence by an additional 56% (600 mcg) and 
44% (300 mcg) in low prevalence areas (10%), and 61% (600 mcg) and 54% (300 mcg) in high 




Details of the study design and procedures were published elsewhere.21 The study was a 
randomized, double-blind, placebo-controlled, parallel 3-arm, superiority trial and was conducted at 
the Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) in Kisumu, western Kenya. The 
dose of ivermectin was based on previous pharmacokinetic modelling which showed that a 3-day 
regimen of 600 mcg/kg/day achieves similar median (5-95 percentiles) maximum drug 
concentrations (Cmax) of ivermectin to single-dose 800 mcg/kg regimens, the highest dose with 
which there was significant clinical experience, while increasing the median time above the lethal 
concentration able to kill 50% of mosquitoes (LC50, 16 ng/mL) from 2 to 7 days. The 300 mcg/kg/day 
dose was chosen at 50% of the higher dose to allow evaluation of the dose response.21 As the 
mosquito feeding involved approximately 150 mosquitoes per feed, the study had a clustered design 
with the patient as the unit of randomization and the mosquito as the unit of analysis. The study was 
approved by the ethics committees of: (1) JOOTRH, (2) Kenya Medical Research Institute [KEMRI], (3) 
Liverpool School of Tropical Medicine, and (4) U.S. Centers for Disease Control and Prevention; the 
latter approving reliance on KEMRI’s ethics committee.  
 
Study Patients 
Adults attending the outpatient departments were eligible if they gave written informed consent, 
had symptomatic uncomplicated P. falciparum malaria confirmed by microscopy or rapid diagnostic 
test, were aged 18-50 years, and agreed to the follow-up schedule. Exclusion criteria included 
pregnancy, breast feeding, known hypersensitivity to ivermectin or DP, QTc ≥460 ms on ECG, body 
mass index (BMI) <16 or ≥32 kg/m2, haemoglobin (Hb) concentration <9 g/dL, history of ivermectin 
use in the last month, DP use in the last 12 weeks, travel to Loa loa endemic countries, history of 
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chronic illness (e.g. HIV-AIDS, TB, diabetes, etc), current use of tuberculosis or anti-retroviral 
medication, and previous enrolment in the same study. 
 
Randomisation and masking 
Patients were randomly assigned (1:1:1) to receive either 0, 300, 600 mcg/kg/day ivermectin for 3 
days (placebo, IVM-3x300, IVM-3x600), co-administered with DP. Because ivermectin accumulates in 
fat tissue,22 potentially acting as a slow-release reservoir, and has a longer effective half-life in 
women,9 randomization was stratified by body mass index (BMI, 2 strata) and sex. An independent 
statistician generated the randomization sequence per strata using permuted blocks of 3. Allocation 
concealment was achieved using sequentially numbered, sealed opaque envelopes. Participants 
were enrolled, randomised and followed-up by study staff. Each participant, regardless of arm, 
received the same number of tablets based on their weight. IVM-3x600 received only ivermectin 
tablets, IVM-3x300 received half the number of ivermectin tablets and an equal number of placebo 
tablets, and the placebo arm received only placebo tablets. 
 
Procedures 
Patients received a bodyweight-based dose of DP (36-75kg: 3 tablets, ≥75kg: 4 tablets of 320/40mg 
Eurartesim®, Sigma Tau, Italy) once-a-day for 3 days, together with ivermectin and/or placebo (45-
55kg: 5 tablets, 55-65kg: 6 tablets, 65-75kg: 7 tablets, 75-85kg: 8 tablets, 85-95kg: 9 tablets, 95-
105kg: 10 tablets of 6mg Iver P® per day [Laboratorio Elea, Argentina]). Ivermectin/placebo tablets 
had a break line, such that half-tablets could be given. All treatment was directly observed. Patients 
were seen on days 2, 7, 10, 14, 21 and 28 for outcome assessments. 
 
Outcomes  
The primary outcome was cumulative mosquito mortality 14 days after membrane feeding 
(henceforth referred to as post-feeding) on blood taken from patients who started the 3-day 
ivermectin/DP regimen 7 days earlier (henceforth referred to as post-treatment). Secondary efficacy 
outcomes were daily survival of mosquitoes up to day 10, 14, or 28 post-feeding performed at days 0 
(enrolment), 2+4 hours (‘day-2+4h’) [Cmax], 7, 10, 14, 21, and 28 post-treatment. Oocyst prevalence 
by PCR was determined 10 days post-feeding for every feed. Safety outcomes included pupil-
diameter, haemoglobin and adverse events, assessed at each post-treatment study visit, aspartate 
transaminase (AST) and alanine transaminase (ALT) measured each visit until day-14, and QT-interval 
determined at days 0, 2 [pre 3rd dose], 2+4h [Cmax], and 28.  
 
Sample Size and Statistical Analysis 
Details of the sample size and power calculations have been published elsewhere,21 in brief: The 
study required 141 participants (47/arm) and was designed (power=80%, α=0.05) to detect a relative 
increase in the 14-day post-feeding cumulative mortality among mosquitoes 7 days post-treatment 
of 30% (RR 1.30) from 24% in the placebo group to 31.2% in the IVM-3x300 group, and a further 25% 
(RR 1.246) increase from 31.2% in IVM-3x300 group to 38.9% with IVM-3x600 group, using clusters 
of 100 anopheline mosquitoes assuming an intracluster correlation coefficient (ICC) of 0.0622,9 and 
allowing for 10% non-feeders and 6.5% loss-to follow-up of participants by day 7. A Statistical 
Analytical Plan was developed prior to analysis.21 The analysis was based on the intention-to-treat 
(ITT) population. The effects on the primary and secondary binary endpoints, were compared using 
log-binomial regression to derive risk ratios (RR) estimated with Generalized Estimating Equations 
(GEE) using an exchangeable covariance structure, taking the cluster design into account. Survival 
time of mosquitoes post-feeding was analysed using Cox-regression with shared frailty to derive 
hazard ratios (HR). Continuous safety outcomes were analysed with GEE models (Gaussian 
distribution, identity link function, exchangeable covariance structures) to derive mean differences, 
or Generalized Linear Models (GLM) when no cluster effect existed for an outcome. Secondary per-
protocol (PP) analysis and multi-variable analysis adjusted for sex, BMI, mosquito age and mosquito 
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crowding was also performed. Per-protocol analysis included participants that took all 3 doses of 
both ivermectin and DP, daily at the same time as the first dose (+/-6 hours), and as per their weight-
band and study-arm allocation. Pre-specified subgroup analysis included sex and BMI. Analyses were 
performed using SAS-v9.4 and Stata-v14.2. Post-hoc population modelling was conducted using the 
Imperial College malaria transmission model to predict the impact of adding ivermectin to MDA on 
all-age malaria prevalence (see Supplementary Appendix).10 A data monitoring committee oversaw 
the study (see Acknowledgements). Trial registration number, ClinicalTrials.gov: NCT02511353. 
 
Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author (MS) and trial statisticians (DW, 
TC) had full access to all the data in the study and MS and FtK had final responsibility for the decision 
to submit for publication. 
 
Results 
Between Jul 20, 2015 and May 7, 2016, 141 patients were randomized (Fig. 1). Baseline 
characteristics were similar between arms (Table 1). Overall, 128 patients (90.8%) attended the 
primary outcome visit 7 days post-treatment (Fig. 1). All mosquitoes contributed to the analyses (no 
missing mosquito data). 
Mosquitoes fed on blood taken from patients 7 days post-treatment had a higher mortality 
by day-14 post-feeding relative to blood from placebo recipients in GEE models (primary analysis) 
(IVM-3x600: RR=2.26, 95% CI 1.93-2.65, p<0.0001; IVM-3x300: RR=2.18, 1.86-2.57, p<0.0001; Table 
S2 in the Supplementary Appendix) and Cox-regression models (secondary analysis) (IVM-3x600: 
HR=6.32, 4.61-8.67, p<0.0001; IVM-3x300: HR=4.21, 3.06-5.79, p<0.0001) (Fig. 2, and Table S3 in the 
Supplementary Appendix). The effect on mosquito mortality declined post-treatment but remained 
significantly increased 28 days post-treatment for IVM-3x600 (HR=1.65, 1.18-2.31, p=0.0034). The 
corresponding figures for IVM-3x300 were: HR=1.33, 0.96-1.84, p=0.08, adjusted HR=1.37, 1.00-1.89, 
p=0.0493 (Fig. 2, and Tables S2-S5 in the Supplementary Appendix). Similar results were seen in per-
protocol and multivariable analyses (Tables S2-S7 in the Supplementary Appendix). IVM-3x600 was 
more lethal than IVM-3x300 (Fig. 2), and this was statistically significant up to 14 days post-
treatment (HR 1.67, 1.19-2.34, p=0.0033) (Tables S2-S7 in the Supplementary Appendix). Sub-group 
analysis showed that the effect was greatest in women (interaction term for sex on day 7 post-
treatment: IVM-3x600, p=0.0078; IVM-3x300: p=0.0087) and patients with an above median BMI 
(≥22 kg/m2) (interaction term for BMI on day 7 post-treatment: IVM-3x600, p=0.0007; IVM-3x300, 
p=0.0019) (Table S8 in the Supplementary Appendix). Mosquito median survival times, for both IVM-
3x600 and IVM-3x300, remained below 10 days (short duration of the extrinsic cycle) for at least 14 
days post-treatment, and remained below 14 days (long duration of the extrinsic cycle) for the entire 
28 day study duration post-treatment. By contrast, median survival in the placebo arm was always 
>14 days for all feeds post-treatment (Fig. 3). Gametocytaemia and oocyst prevalence were low in all 
study arms from baseline onwards (Table S9). 
Two serious adverse events (SAEs) were reported: one QT-prolongation of 510 ms with T-
wave inversion in the IVM-3x300 group and one anaphylactic reaction to likely piperaquine or 
ivermectin, in the IVM-3x600 group (Table 2, and Table S10 in the Supplementary Appendix). The 
latter was the only patient who discontinued treatment due to adverse events.  
Relative to placebo, more ivermectin recipients experienced an adverse event (AE): 10/45 
(22%) with IVM-3x600, 4/48 (8%) with IVM-3x300, and 3/46 (7%) with placebo (risk difference IVM-
3x600: 15.7%, 1.6%-29.8%, p=0.0289; IVM-3x300: 1.8%, -8.8% to 2.4%, p=0.74) (Table 2). Related 
AE’s showed evidence of a dose-response, predominantly reflecting transient minor visual 
disturbances: 4/45 (9%) with IVM-3x600, 2/48 (4%) with IVM-3x300, and 0/46 (0%) with placebo 
(risk difference IVM-3x600: 8.9%, 0.6%-17.2%, p=0.0360; IVM-3x300: 4.2%, -4.0% to 12.3%, p=0.32) 
(Table 2, and Tables S11-S13 in the Supplementary Appendix). All AE’s were non-severe (grade ≤2), 
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except for 3 patients with pre-existing liver enzyme elevations (grade-1: n=2, grade-3: n=1) who 
exhibited grade-3 elevations post-treatment (Table S14 in the Supplementary Appendix). 
Maximum change from baseline in QTcF-interval (on day 2+4h), pupil diameter, AST and ALT 
values (during follow-up), and malaria recurrence did not differ between treatment groups (Table 2). 
There was a greater fall in haemoglobin in IVM-3x600 vs placebo (-1.9 vs -1.5 g/dL; mean difference -
0.35 [-0.64, -0.05], p=0.0202). The maximum fall in the IVM-3x300 group was -1.7 g/dL (mean 
difference vs placebo -0.10 [-0.39, 0.19], p=0.49) (Fig. S3-S7 and Tables S15-S19 in the 
Supplementary Appendix). 
The Imperial College malaria transmission model predicted that adding IVM-3x600 or IVM-
3x300 to MDA with DP could result in greater reductions in all-age population prevalence of malaria 
versus DP alone, particularly in low-transmission settings (baseline prevalence 10%), where it results 
in the prevalence remaining <0.1% for over 6 months, indicating that local elimination would be 




The addition of 3-days of 300 or 600 mcg/kg/day ivermectin to a standard 3-day treatment course of 
DP was well tolerated and associated with a marked impact on A. gambiae s.s. mortality among 
laboratory-reared mosquitoes that had fed on blood taken from ivermectin treated patients. The 
mosquitocidal effects were much stronger and lasted 28 days compared to 7 days observed in 
previous studies using the standard 200 mcg/kg single dose (on day-0) or repeated doses (on days 0 
and 2).9 Parameterising post-feeding mosquito mortality rates in the Imperial College malaria 
transmission model using estimates from this trial predicted that adding either ivermectin 300 or 
600 mcg/kg/day for 3 days to repeated rounds of MDA with DP would provide at least a 50% boost 
to the population-level impact on malaria transmission reduction. The combination of an ACT and 
ivermectin targets both the malaria parasite and its vector, a unique property amongst malaria 
interventions that has the potential to reduce the onward transmission of antimalarial drug resistant 
parasites. These regimens’ long effect-duration, tolerability and unique mosquito killing action, make 
ivermectin a promising new tool for malaria elimination. 
The >50% predicted boost to the impact of MDA, even with 300 mcg/kg/day, is remarkable 
especially against a background of existing LLIN use, and is much higher than the estimated effect of 
adding low-dose primaquine.23 Whereas primaquine only prevents transmission from individuals 
that are gametocytemic, all individuals receiving ivermectin contribute to suppressing the vector 
population regardless of whether they have malaria or are gametocytemic. Reduced mosquito 
numbers plus the killing of mosquitoes before any ingested gametocytes complete sporogony, help 
to prevent the resurgence of transmission during the waning of DP’s prophylactic period. It is 
possible that the modelled estimates for ivermectin are conservative, as mosquitoes in the wild, that 
endure adverse natural conditions, might be more vulnerable to its lethal effects than mosquitoes 
kept in a laboratory in optimal survival conditions. Furthermore, we only considered the impact on 
the life-span of the mosquitoes, and not any secondary effects such as the impact on fecundity, or 
the ability of affected but surviving mosquitoes to fly, feed and/or transmit malaria.3, 5 
The observed 28-day mosquitocidal effect was longer than the 7-days predicted by our 
pharmacodynamic simulation model based on published pharmacokinetic parameters of ivermectin 
and LC50 values for A.gambiae.21 Three previous human studies have assessed the long-term effect 
of ivermectin on mosquito survival.4, 6, 9 An early study found that a single-dose of 250 mcg/kg in a 
human volunteer (N=1) had an effect for 2 weeks post-treatment,4 but subsequent trials with a 
single-dose of 200 mcg/kg showed no effect on mosquito survival at 14 days post-treatment6 and a 
repeated dose of 200 mcg/kg given on days 0 and 2 showed only a modest effect on survival 7-days 
post-treatment.9 Further pharmacokinetic and pharmacodynamic modelling of our data is ongoing 
to determine whether this prolonged mosquitocidal effect is due to an unidentified active ivermectin 
metabolite, or can be solely explained by residual concentrations of the parent compound. Future 
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studies should also assess any potential drug-drug interactions between ivermectin and possible 
antimalarial partner drugs, including dihydroartemisinin-piperaquine, sulfadoxine-pyrimethamine-
amodiaquine, and triple ACT’s. In this study we did not see any effect of ivermectin on piperaquine 
induced QT-prolongation. The current study also intended to assess ivermectin’s sporogonic effect, 
however gametocyte and oocyst rates were already low pre-treatment, perhaps unsurprising in this 
malaria exposed, adult population; future studies assessing in vivo effects on sporogony might 
consider enrolling only gametocytaemic individuals. 
The study allocation was stratified by sex and BMI as these are known determinants of the 
pharmacokinetics of ivermectin.9 Sub-group analysis confirmed that the effect of ivermectin on 
mosquito mortality was significantly greater in women, and in those with higher BMI. The greater 
effect in women could have been driven by accumulation of ivermectin in fat tissue,22 as within the 
inclusion range of our study (age: 18-50; BMI: 16-32), at an equal age and BMI, women have 1.3-2.5 
times more body-fat than men.24  
There is extensive experience with ivermectin attesting to its safety. Ivermectin’s excellent 
safety profile can be explained by its principal pharmacological mechanism of action; in 
invertebrates, ivermectin causes the opening of glutamate-gated chloride channels resulting in 
flaccid paralysis and death.2 Glutamate-gated chloride channels do not exist in humans. Other 
weakly sensitive channels are found in the human central nervous system, but the blood-brain 
barrier limits drug access to these channels.2 Severe adverse events have predominantly been in 
individuals with Loa loa, likely due to rapid lysis of parasite biomass.25 In areas endemic for Loa loa 
filariasis, pre-treatment assessment of individuals for Loa loa is recommended.26  
In previous studies in >400 individuals, single-dose ivermectin ≥800 mcg/kg, achieving 
similar predicted Cmax as IVM-3x600, was safe and well tolerated.21 In the current study, both high-
dose ivermectin regimens seemed well tolerated overall, although more patients experienced AEs 
over the 28-day follow-up period with IVM-3x600 (22%) compared to placebo (7%) and IVM-3x300 
(8%) (Table 2). This was partially explained by a higher number of patients with pneumonia, but 
these were unlikely due to ivermectin as only one occurred in the week of ivermectin administration 
and with no cases in the IVM-3x300 group there was no evidence of a dose-response. However, 
ivermectin was associated with dose-dependent visual disturbances during the dose-administration 
period (4 and 2 cases in the IVM-3x600 and IVM-3x300 groups respectively vs none in the placebo 
group). These were all mild, transient and of short duration (a few minutes to a few hours), 
consistent with transient subjective ocular complaints reported in previous onchocerciasis studies, 
which could not be explained by microfilaria concentrations and were hypothesized to reflect mild 
dose-related toxic effects of ivermectin.17-19  IVM-3x600 was also associated with a 0.35 g/dL greater 
fall in haemoglobin, but the clinical relevance of this is unclear as by 28 days post-treatment 
haemoglobin concentrations were similar. It warrants further exploration in future studies to 
determine if this was a chance finding, as this did not occur with IVM-3x300 and ivermectin is not 
known to decrease hemoglobin.13 As expected, DP was associated with prolongation of the QTc-
interval, which exceeded 500ms in one patient. However, there was no suggestion that the 
piperaquine-induced QT-prolongation differed between the arms. One IVM-3x600 patient developed 
an anaphylactic reaction after the first dose of DP and ivermectin which resolved rapidly following 
treatment. Allergic and anaphylactic reactions are known side-effects of both DP and ivermectin. 
Since, the same patient tolerated artemether-lumefantrine, which also contains an artemisinin 
derivative, the reaction may reflect the use of piperaquine or ivermectin. Three patients had grade-3 
elevated liver enzymes; while all had pre-existent increases, two were just above the upper-limit of 
normal (grade-1) at baseline and increased to grade-3, whereas the third had grade-3 elevation at 
baseline. Liver enzyme increases are known to be caused by both ivermectin and DP. The frequency 
of liver enzyme elevations, allergic reactions to either DP or ivermectin, and the subjective visual 
complaints may be important determinants of the potential use of IVM-3x600 or IVM-3x300 as part 
of MDA requiring further evaluation in larger population based studies.  
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 A limitation of this study is that it enrolled participants with symptomatic malaria, whereas 
possible future applications of IVM-3x600 or IVM-3x300 may involve MDA with artemisinin-based 
combination therapies (ACTs) targeting mostly asymptomatic carriers and uninfected individuals. 
Symptomatic patients were chosen as this group was thought to potentially benefit from, and be the 
most likely to comply with, the frequent follow-up schedule. Although it is not likely that 
symptomatic malaria significantly modifies the mosquitocidal effect of ivermectin, it remains to be 
determined if the good tolerance of IVM-3x600 and IVM-3x300 ivermectin observed in our study 
applies to uninfected and asymptomatic individuals. This should be assessed in future (field) studies. 
A further limitation recognises that programme implementation for malaria prevention will also 
include children, and use multiple MDA rounds. It is thus important further pharmacokinetic, 
tolerability, safety and efficacy studies be conducted with repeated courses of ivermectin, as well as 
among children, whose pharmacokinetics of ivermectin may differ from that in adults. The 
population-level model presumed similar efficacy in children ≥4 years as in adults, as no studies were 
identified that assessed the pharmacokinetics of ivermectin in children. In areas of piperaquine 
resistance such as the Greater Mekong Sub-region, future studies should assess the safety and 
efficacy of ivermectin when used in combination with other ACTs, including with Triple ACT’s 
(TACT’s).27 Another possible limitation is that this study used a homogeneous laboratory-reared 
mosquito colony known to be sensitive to pyrethroids and other classes of public health insecticides 
which may not be reflective of wild populations. However, previous work has demonstrated that 
ivermectin affects survival of all tested anophelines (≥17 species tested),28 and there is no evidence 
that pyrethroid resistance mechanisms cross-target ivermectin,3 thus there is no reason to believe 
the findings from this study would be much different for other anopheles species. Nevertheless, 
future studies would be beneficial to examine possible (heterogeneity of) effects of ivermectin 
against wild populations and other species, including examining any possible cross-resistance with 
other insecticides. Although no resistance in mosquitoes has been described following decades of 
ivermectin MDA for onchocerciasis and lymphatic filariasis, vigilant resistance monitoring should be 
ensured if high-dose ivermectin is deployed at scale. Based on An.gambiae anthropophily, the model 
assumed 92% of bloodmeals are taken from humans, however in areas where more zoophilic vectors 
such as An.arabiensis are prevalent, administering endectocides to animals may be considered 
though the impact of such intervention remains to be explored. Furthermore, we did not adjust for 
multiple comparisons as per the protocol and the statistical analysis plan, although published views 
regarding this differ. Lastly, the model does not take importation of new infections into the area into 
account which results in more optimistic predictions about the impact of MDA with ivermectin. 
Estimating realistic importation rates is problematic as this is highly heterogenous in different areas 
and at different times of the transmission season and depends on the size of the implementation 
area. 
The relatively small difference in predicted impact between IVM-3x300 and IVM-3x600 in 
the Imperial College malaria transmission model reflects the difference between daily-mortality and 
cumulative-mortality in the first 10- to 14-days post-feeding; the latter being the main determinant 
of transmission potential in the model. Although with IVM-3x300 more mosquitoes survive for 2-
days, which is the time when they are due for their next, potentially infectious, bloodmeal, by the 
time that they have completed sporogony and become infectious, i.e. from around 10-days post-
feeding onward, the difference in cumulative mortality, and thus the potential for onwards 
transmission, is smaller. This is illustrated by a lack of difference in mosquitocidal effect at day-7 
post-treatment between the 600 and 300 mcg/kg/day dose in the GEE model (RR=1.03, Table S2), 
which compares cumulative-mortality, versus the Cox model (HR=1.50, Table S3), which compares 
daily hazards. The difference between IVM-3x600 and IVM-3x300 becomes more apparent post-
treatment from day 10 onwards when ivermectin levels wain further (Table S2). Our data suggests 
that a dose of IVM-3x300 would provide a good balance between efficacy and tolerance, considering 
the limited difference in cumulative-efficacy and the higher rate of AE’s with IVM-3x600. The 
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relatively wide therapeutic index of ivermectin, also suggests that practical dosing regimens could be 
considered that are based on age or height, or fewer weight-strata than used in the current study. 
High-dose ivermectin could potentially also have important implications for other vector-
borne diseases, transmitted by Aedes mosquitoes (incl. zika, dengue, chikungunya, and yellow fever) 
or Culex mosquitoes (incl. West Nile fever, lymphatic filariasis, and Japanese encephalitis), and other 
insect- and tick-borne diseases (incl. sleeping sickness and Lyme disease).3 Ivermectin is already 
being distributed at scale for lymphatic filariasis and onchocerciasis control. Combining high-dose 
ivermectin MDA for malaria with these other programs could offer many synergistic benefits in 
terms of logistics and cost-savings in areas where these diseases are co-endemic.29 Furthermore, it 
could be considered to distribute high-dose ivermectin as part of seasonal malaria chemoprevention 
(SMC), which also involves 3-day regimens and monthly population-based campaigns 3-4 times per 
year, and this could include older siblings and adults living in the same communities as children 
targeted by SMC.30 
 This study showed that ivermectin 600 or 300 mcg/kg/day for 3 days was well-tolerated and 
able to kill mosquitoes feeding on humans for at least 28 days post-treatment, making ivermectin a 
promising new tool for malaria elimination. Next steps should include assessing high-dose 
ivermectin’s safety, tolerability, mosquitocidal efficacy and pharmacokinetics in younger age groups, 
and with repeated courses, before its effect on malaria transmission can be assessed through MDA. 
 
List of abbreviations 
95% CI 95 percent Confidence Interval 
ACT Artemisinin-based combination therapy 
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CDC Centers for Disease Control and Prevention 
Cmax Maximum drug concentration 
DP Dihydroartemisinin-piperaquine 
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GLM Generalized Linear Model 
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Figure 1: Enrolment, Randomisation, and Follow-up. 
741 adults with malaria
assessed for eligibility
600 excluded
540 not meeting eligibility criteria
60 declined to participate
141 randomised
46 assigned to Placebo
46 received all  3 allocated doses
44 attended Day 7 (prim. outcome)
2 lost to follow-up
40 attended Day 28 (last visit)




44 (95.7%) mosquito feeding (D7)
Secondary outcomes
42 (91.3%) mosquito feeding (D2+4h)
36 (78.3%) mosquito feeding (D10)
40 (87.0%) mosquito feeding (D14)
37 (80.4%) mosquito feeding (D21)
38 (82.6%) mosquito feeding (D28)
46 (100%) pupil diameter (max)
44 (95.7%) electrocardiogram (D2+4h) 
46 (100%) haemoglobin (nadir)
46 (100%) malaria response
Per protocol population 
45 treated per protocol
1 not treated per protocol
1 one dose too late (+19h)
Primary outcome
43 (93.5%) mosquito feeding (D7)
Secondary outcomes
41 (89.1%) mosquito feeding (D2+4h)
35 (76.1%) mosquito feeding (D10)
39 (84.8%) mosquito feeding (D14)
37 (80.4%) mosquito feeding (D21)
37 (80.4%) mosquito feeding (D28)
45 (97.8%) pupil diameter (max)
43 (93.5%) electrocardiogram (D2+4h) 
45 (97.8%) haemoglobin (nadir)
45 (97.8%) malaria response
48 assigned to IVM-3x300
47 received all  3 allocated doses
1 did not receive all  3 allocated 
doses
1 withdrew consent
41 attended Day 7 (prim. outcome)
2 lost to follow-up
2 withdrew consent
3 missed visit (returned later)
41 attended Day 28 (last visit)




41 (85.4%) mosquito feeding (D7)
Secondary outcomes
45 (93.8%) mosquito feeding (D2+4h)
37 (77.1%) mosquito feeding (D10)
39 (81.3%) mosquito feeding (D14)
39 (81.3%) mosquito feeding (D21)
39 (81.3%) mosquito feeding (D28)
47 (97.9%) pupil diameter (max)
45 (93.8%) electrocardiogram (D2+4h) 
47 (97.9%) haemoglobin (nadir)
47 (97.9%) malaria response
Per protocol population 
46 treated per protocol
2 not treated per protocol
1 withdrew consent
1 wrong weight band, 
given 6 instead of 5 tablets/day
Primary outcome
40 (83.3%) mosquito feeding (D7)
Secondary outcomes
44 (91.7%) mosquito feeding (D2+4h)
36 (75.0%) mosquito feeding (D10)
38 (79.2%) mosquito feeding (D14)
38 (79.2%) mosquito feeding (D21)
38 (79.2%) mosquito feeding (D28)
46 (95.8%) pupil diameter (max)
44 (91.7%) electrocardiogram (D2+4h) 
46 (95.8%) haemoglobin (nadir)
46 (95.8%) malaria response
47 assigned to IVM-3x600
43 received all  3 allocated doses
4 did not receive all  3 allocated 
doses
1 missed one dose of ivermectin
1 anaphylactic reaction, 
last two doses withheld
1 withdrawn due to drunkenness
43 attended Day 7 (prim. outcome)
2 lost to follow-up
2 withdrew consent
37 attended Day 28 (last visit)




43 (91.5%) mosquito feeding (D7)
Secondary outcomes
41 (87.2%) mosquito feeding (D2+4h)
39 (83.0%) mosquito feeding (D10)
40 (85.1%) mosquito feeding (D14)
35 (74.5%) mosquito feeding (D21)
34 (72.3%) mosquito feeding (D28)
45 (95.7%) pupil diameter (max)
42 (89.4%) electrocardiogram (D2+4h) 
44 (93.6%) haemoglobin (nadir)
44 (93.6%) malaria response
Per protocol population 
41 treated per protocol
6 not treated per protocol
1 missed one dose of ivermectin
1 anaphylactic reaction, 
last two doses withheld
1 withdrawn due to drunkenness
1 withdrew consent
1 one dose of DP too late (+19h)
1 one dose too early (-6.2h*)
Primary outcome
40 (85.1%) mosquito feeding (D7)
Secondary outcomes
38 (80.9%) mosquito feeding (D2+4h)
36 (76.6%) mosquito feeding (D10)
37 (78.7%) mosquito feeding (D14)
33 (70.2%) mosquito feeding (D21)
31 (66.0%) mosquito feeding (D28)
41 (87.2%) pupil diameter (max)
40 (85.1%) electrocardiogram (D2+4h) 
41 (87.2%) haemoglobin (nadir)






















 IVM-3x600=ivermectin 600 mcg/kg/day for 3 days. IVM-3x300=ivermectin 300 mcg/kg/day for 3 days. 
*As per the protocol, dosing should take place daily at the same time as the first dose (+/-6 hours). 
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Age (years) 25.4 (6.0) 25.5 (6.9) 25.1 (5.0) 
Sex    
   Male 27 (57%) 29 (60%) 27 (59%) 
   Female 20 (43%) 19 (40%) 19 (41%) 
Body mass index (kg/m2) 22.5 (2.9) 22.0 (3.1) 22.3 (2.8) 
Pupil diameter (mm) 4.2 (0.6) 4.2 (0.7) 4.4 (0.7) 
QTcF interval (ms) 397 (20) 400 (22) 398 (21) 
Haemoglobin (g/dL) 14.1 (2.2) 14.2 (1.8) 13.9 (1.7) 
AST (iu/L) 35.5 (36.0) 27.3 (8.6) 29.7 (27.1) 
ALT (iu/L) 25.1 (24.1) 19.5 (10.1) 19.6 (13.5) 
Parasite density (per µL) 2,939 (1,574-5,490) 6,557 (4,109-10,464) 3,403 (1,969-5,880) 
Data are n (%), mean (SD), or geometric mean (95% confidence interval). IVM-3x600=ivermectin 600 
mcg/kg/day for 3 days. IVM-3x300=ivermectin 300 mcg/kg/day for 3 days. QTcF=electrocardiogram QT 
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Figure 2: Mosquito survival following feeding at different time points post-treatment on blood from 
patients who received IVM-3x600, IVM-3x300, or Placebo. 
Baseline 
 
Day 2+4h (Cmax) 
 










Summary of HR’s by patient visit 
 
Hazard ratio (HR) and 95% confidence interval (95% CI) by study arm relative to placebo for mosquito mortality by 
day 14 using Cox regression adjusted for mosquito clusters. See the Supplementary Appendix for hazard ratios of: 
IVM-3x600 versus IVM-3x300, and adjusted and per-protocol analyses (Tables S3 and S7). IVM-3x600=ivermectin 
600 mcg/kg/day for 3 days. IVM-3x300=ivermectin 300 mcg/kg/day for 3 days.  
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Figure 3: Median survival times of mosquitoes following feeding on patients’ blood at different 
time points post-treatment 
 
Median survival times and interquartile range of mosquitoes feeding at different days post-
treatment. Dashed horizontal lines represent the longest (14 days) and shortest (10 days) duration 
of the extrinsic cycle of P. falciparum in Anopheles gambiae s.s. in western Kenya. IVM-
3x600=ivermectin 600 mcg/kg/day for 3 days. IVM-3x300=ivermectin 300 mcg/kg/day for 3 days. 
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Mean*†‡ or Risk# difference (95% CI), p-value 
IVM-3x600 vs Placebo IVM-3x300 vs Placebo IVM-3x600 vs IVM-3x300 
Pupil diameter (max), maximum increase from baseline 
during follow-up (mm) 
0.5 (0.4) (n=45) 0.5 (0.4) (n=47) 0.4 (0.4) (n=46) 0.09 (-0.07, 0.25), 0.28† 0.08 (-0.08, 0.23), 0.33† 0.01 (-0.15, 0.18), 0.88† 
QTcF interval (Day 2+4h), change from baseline (ms) 27 (17) (n=42) 33 (17) (n=45) 29 (18) (n=44) -0.8 (-8.0, 6.5), 0.84‡ 4.7 (-2.6, 11.9), 0.21‡ -5.4 (-12.3, 1.5), 0.13‡ 
QTcF interval (Day 2+4h), ≥500 ms 0/42 (0%) 1/45 (2.2%) 0/44 (0%) 0.0% (-0.4%, 3.7%), 1.00# 2.2% (-1.4%, 5.8%), 0.23# -2.2% (-5.9%, 1.5%), 0.24# 






35.8 (-107.2, 178.7), 0.62* 28.9 (-108.1, 165.9), 0.68* 6.9 (-126.3, 140.0), 0.92* 
AST (max), maximum increase from baseline during 
follow-up (iu/L) 
10 (38) (n=33) 5 (9) (n=42) 6 (11) (n=43) 4.0 (-9.3, 17.4), 0.56† -0.9 (-5.0, 3.3), 0.69† 4.9 (-8.3, 18.1), 0.47† 
   with normal baseline (<45 iu/L) 3 (6) (n=29) 5 (9) (n=39) 5 (10) (n=40) -2.6 (-6.2, 1.0), 0.16† -0.3 (-4.3, 3.8), 0.90† -2.3 (-5.8, 1.1), 0.18† 
   with abnormal baseline (≥45 iu/L) 62 (106) (n=4) 5 (9) (n=3) 14 (24) (n=3) 48.3 (-49.5, 146.0), 0.33† -8.7 (-33.9, 16.6), 0.50† 56.9 (-38.4, 152.2), 0.24† 
AST, development of elevation§ (≥45 iu/L) 1/29 (3%) 2/39 (5%) 2/40 (5%) -1.6% (-11.7%, 8.6%), 0.77# 0.1% (-9.3%, 9.5%), 0.98# -1.7% (-11.9%, 8.6%), 0.75# 
ALT (max), maximum increase from baseline during 
follow-up (iu/L) 
9 (24) (n=41) 7 (13) (n=46) 9 (21) (n=46) -0.4 (-9.8, 9.0), 0.94† -2.5 (-9.6, 4.5), 0.49† 2.1 (-6.2, 10.4), 0.62† 
   with normal baseline (<35 iu/L) 6 (12) (n=34) 5 (10) (n=42) 8 (19) (n=43) -2.4 (-9.4, 4.6), 0.51† -3.3 (-9.8, 3.2), 0.32† 0.9 (-4.2, 6.0), 0.73† 
   with abnormal baseline (≥35 iu/L) 23 (53) (n=7) 24 (28) (n=4) 22 (38) (n=3) 1.1 (-51.1, 53.3), 0.97† 2.5 (-41.1, 46.1), 0.91† -1.4 (-46.5, 43.7), 0.95† 
ALT, development of elevation§ (≥35 iu/L) 4/34 (12%) 4/42 (10%) 4/43 (9%) 2.5% (-11.2%, 16.2%), 0.73# 0.2% (-12.7%, 13.2%), 0.97# 2.2% (-11.5%, 16.0%), 0.75# 
Haemoglobin (nadir), maximum decrease from baseline 







-0.35 (-0.64, -0.05), 0.0202† -0.10 (-0.39, 0.19), 0.49† -0.24 (-0.58, 0.09), 0.15† 
Haemoglobin; development of moderate anaemia§ (<9 
g/dL) 
2/44 (5%) 2/47 (4%) 1/46 (2%) 2.4% (-5.5%, 10.2%), 0.55# 2.1% (-5.7%, 9.8%), 0.60# 0.3% (-7.5%, 8.1%), 0.94# 
Malaria recurrence, between day 2 to 28 0/44 (0%) 0/47 (0%) 0/46 (0%) - - - 
Serious Adverse Events~ (SAE) 1/45 (2%) 1/48 (2%) 0/46 (0%) 2.2% (-2.7%, 7.2%), 0.38# 2.1% (-2.8%, 6.9%), 0.40# 0.1% (-4.7%, 5.0%), 0.96# 
Adverse Events~ (AE)       
   Participants with ≥1 AE 10/45 (22%) 4/48 (8%) 3/46 (7%) 15.7% (1.6%, 29.8%), 0.0289# 1.8% (-8.8%, 2.4%), 0.74# 13.8% (-0.6%, 28.3%), 0.06# 
   Participants with ≥1 AE, related 5/45 (11%) 2/48 (4%) 0/46 (0%) 11.1% (2.2%, 20.0%), 0.0143# 4.2% (-4.6%, 12.9%), 0.35# 6.9% (-1.9%, 15.7%), 0.12# 
   Transient minor visual disturbances~ 4/45 (9%) 2/48 (4%) 0/46 (0%) 8.9% (0.6%, 17.2%), 0.0360# 4.2% (-4.0%, 12.3%), 0.32# 4.7% (-3.5%, 12.9%), 0.26# 
Data are mean (SD), median (IQR), or n/N (%), unless otherwise specified. IVM-3x600=ivermectin 600 mcg/kg/day for 3 days. IVM-3x300=ivermectin 300 mcg/kg/day for 3 days. 
QTcF=electrocardiogram QT interval, corrected for heart rate using Fredericia’s formula. AST=aspartate transaminase. ALT=alanine transaminase. 
* Mean difference (95% CI), p-value: obtained from GLM models. 
† Mean difference (95% CI), p-value: obtained from GLM models adjusted for baseline measurement. 
‡ Mean difference (95% CI), p-value: obtained from GEE models adjusted for baseline measurement and repeated measures.  
# Risk Difference (95% CI), p-value: obtained from GLM models. 
§ Incident abnormal values in those with normal values at baseline. 
~ See Supplementary Appendix for case descriptions of SAE’s and transient minor visual disturbances, and a full list of AE’s by system organ class (Tables S10-S13). 
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Figure 4: Population modelling of predicted impact on malaria prevalence in high and low 
transmission settings 
 
High transmission (30% baseline prevalence) 
 
 
Low transmission (10% baseline prevalence) 
 
DP=dihydroartemisinin-piperaquine for 3 days. IVM-1x150=ivermectin 150 mcg/kg for 1 day. IVM-
3x300=ivermectin 300 mcg/kg/day for 3 days. IVM-3x600=ivermectin 600 mcg/kg/day for 3 days. 
The Imperial College malaria transmission model predicted that adding IVM-3x600 to mass drug 
administration with DP (4 rounds per year one month apart towards the end of the dry season for 2 years; 
indicated with red arrows) could result in a greater 2-year-mean reduction in all-age population prevalence 
of malaria (61.0% and 55.6% relative risk reduction [RRR]) in high and low transmission areas respectively). 
For IVM-3x300 this was 54.3% and 44.4% (Fig. S8-S11 and Tables S20-S21 in the Supplementary Appendix). 
In low transmission settings, DP plus IVM-3x300 or IVM-3x600 could reduce slide prevalence to <0.1% for 
over 6 months, meaning that elimination could occur in the absence of importation. 
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